Compare · LNAI vs NVO
LNAI vs NVO
Side-by-side comparison of Lunai Bioworks Inc. (LNAI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNAI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 20442.2x LNAI ($10.6M).
- Over the past year, LNAI is down 89.3% and NVO is down 29.3% - NVO leads by 60.0 points.
- NVO has hit the wire 4 times in the past 4 weeks while LNAI has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for LNAI).
- Company
- Lunai Bioworks Inc.
- Novo Nordisk A/S
- Price
- $2.71-0.73%
- $48.78+1.22%
- Market cap
- $10.6M
- $215.95B
- 1M return
- -20.41%
- +2.89%
- 1Y return
- -89.32%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LNAI
- Lunai Bioworks Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
- Lunai Bioworks Inc. filed SEC Form 8-K: Other Events
- Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
- Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
- Lunai Bioworks Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
- SEC Form 10-Q filed by Lunai Bioworks Inc.
- Lunai Bioworks Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S